Plus, news about Ventyx Biosciences, CEPI, Evolus, Recursion and Sensorion:
Lexeo Therapeutics raises $95M: The financing is nearly the same size as the gene therapy maker’s $100 million IPO four months ago. The new money from Novo Holdings and other investors is expected to give the clinical-stage biotech runway into 2027. — Kyle LaHucik
Nurix Therapeutics gets FDA go-ahead to continue trial: The regulator lifted its partial hold on Nurix’s Phase Ia/Ib clinical trial investigating NX-2127 to treat B-cell malignancies. The FDA halted the trial in November after the company said it wanted to change the manufacturing process for the drug. NX-2127 works by degrading BTK and IMiD neosubstrates. — Anna Brown
Ventyx Biosciences’ stock sinks on pipeline reorganization: The San Diego startup announced plans to shift focus to two NLRP3 inhibitor programs and partner out a third program, VTX002. Last October, VTX002 succeeded in a Phase II study in ulcerative colitis but analysts wondered whether it could compete with other programs. The reorganization follows a $100 million PIPE announced on Thursday. Ventyx shares $VTYX fell about 20% on Monday. — Max Gelman
CEPI raises $57 million for Covid-19 challenge trials: The studies will examine the effectiveness of nasal and inhaled vaccines in preventing Covid-19. Researchers from Imperial College London will lead the five-year international project. — Max Gelman
Evolus prices $50M offering: The California medical aesthetics company expects to raise the money to grow its neurotoxin Jeuveau business and its line of dermal fillers. — Kyle LaHucik
Recursion opens a London office: The Salt Lake City biotech and its subsidiary Valence Lab are launching in London, with plans to open a new office in King’s Cross in June. The company also appointed Michael Bronstein, an artificial intelligence professor at the University of Oxford, as a scientific advisor. — Anna Brown
Sensorion’s hearing preservation drug reaches proof of concept: The biotech’s SENS-401 met the primary endpoint in a Phase IIa test of 28 patients who underwent a cochlear implant. The study has now finished, and complete data are set to be published in the third quarter. SENS-401 is also in a Phase II trial for the prevention of cisplatin-induced ototoxicity. — Ayisha Sharma
https://endpts.com/lexeo-brings-in-95m-fda-lifts-hold-on-nurix-cancer-trial/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Groundbreaking CoCas9 Enzyme Unveiled: A Compact and Efficient CRISPR Tool for Genetic Therapy
Introduction: A revolutionary stride has been made in the field of genetic engineering, as researchers from the University of Trento introduce a novel CRISPR enzyme, CoCas9, which promises to enhance the delivery and efficacy of in vivo gene therapy using...
Pfizer’s New Gene Therapy BEQVEZ™ Wins FDA Approval for Hemophilia B
In a notable advancement for hemophilia treatment, Pfizer Inc. (NYSE: PFE) has received U.S. Food and Drug Administration approval for BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy aimed at adults suffering from moderate to severe hemophilia B. This...
Astellas Teams Up with Poseida Therapeutics for Innovative CAR-T Cell Therapy Development
Astellas Pharma, through its subsidiary Xyphos Biosciences, has entered into a second collaborative agreement with Poseida Therapeutics to pioneer the development of off-the-shelf cell therapies for solid tumors. This follows their initial partnership in 2023, which...
Cytiva Introduces New Cell Manufacturing Lines for Viral Vectors
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and...
Related Services
Plasmids GMP Services
AAV GMP Services
